New hope for tough childhood cancer: experimental drug targets aurora kinase

NCT ID NCT04106219

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called LY3295668 erbumine in children whose neuroblastoma has returned or not responded to treatment. The study aims to find a safe dose and see if the drug can shrink tumors, either alone or with standard chemotherapy. About 71 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3295668 erbumine (aurora kinase A inhibitor)
What this could lead to: If successful, this could lead to a new treatment option for children with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong: This is an early Phase 1 trial focused on safety, so it is too soon to know if the drug works. Side effects may be significant, and the drug may not shrink tumors in most participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

Alder Hey Children's Hospital

Liverpool, L14 5AB, United Kingdom
Centre Leon Berard

Lyon, Auvergne-Rhône-Alpes, 69373 CEDEX 08, France
Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Cincinnati Childrens Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Hospital Infantil Universitario Niño Jesús

Madrid, 28009, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Barcelona [Barcelona], 8035, Spain
Institut Curie

Paris, 75248, France
Istituto Nazionale dei Tumori

Milan, Lombardy, 20133, Italy
National Cancer Center Hospital

Chuo-ku, Tokyo, 104-0045, Japan
Perth Children's Hospital

Perth, Western Australia, 6009, Australia
Texas Childrens Hospital

Houston, Texas, 77030, United States
UCSF Medical Center at Mission Bay

San Francisco, California, 94158, United States
UZ Gent

Ghent, Oost-Vlaanderen, 9000, Belgium
University of Chicago - Comer Children's Hospital

Chicago, Illinois, 60637, United States
Universitätsklinikum Köln

Cologne, 50924, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.